STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.43
−1.73%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.88
- Revenue estimate
- $8.2M
Latest reported
- Last report date
- Aug 3, 2026
- EPS actual
- -$0.93
- EPS estimate
- -$0.80
- Revenue actual
- $9.3M
- Revenue estimate
- $4.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1.6%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $47
- PT range
- $35 – $60
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 3, 2026 | -$0.80 | -$0.93 | Miss -16.98% | $9.3M |
| May 7, 2026 | -$0.80 | -$0.79 | Beat 1.25% | $6.2M |
| Nov 4, 2025 | -$0.54 | -$0.65 | Miss -20.37% | $10.6M |
| Aug 12, 2025 | -$0.57 | -$0.40 | Beat 29.82% | $13.8M |
| Mar 18, 2025 | -$0.51 | -$0.18 | Beat 64.71% | $22.6M |
| May 4, 2023 | -$0.70 | -$0.53 | Beat 24.29% | $5.2M |
| Mar 6, 2023 | -$0.72 | -$0.65 | Beat 9.72% | $3.3M |
| Nov 14, 2022 | -$0.69 | -$0.66 | Beat 4.35% | $2.9M |
| Mar 10, 2022 | -$0.62 | -$0.66 | Miss -6.45% | — |
| Aug 10, 2021 | -$0.49 | -$0.60 | Miss -22.45% | — |
| Mar 9, 2021 | -$0.43 | -$0.42 | Beat 2.33% | — |
| Nov 12, 2020 | -$0.42 | -$0.41 | Beat 2.38% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026